A pan-allelic human SIRPα-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response

Authors: Xiaofeng Niu, Chunnian Wang, Haixia Jiang, Rui Gao, Yefeng Lu, Xiaoli Guo, Hongping Zhou, Xue Cui, Jun Sun, Quan Qiu, Dawei Sun, Hongtao Lu

Journal: Antibody Therapeutics

PubMed ID: 39257438

DOI: https://doi.org/10.1093/abt/tbae022

Products & Services: Two human IgG4 anti-SIRPα reference antibodies, HEFLB and hu1H9, were produced at Biointron according to patents WO 2017/178653 A2 and WO 2019/023347 Al. Anti-PD-L1 single-domain antibody KN035 was produced at Biointron according to patent CN 111116747 A (SEQ ID NO: 33). Anti-SIRPγ antibody LSB2.20 was purchased from Biolegend. Human IgG1, human IgG4, and mouse IgG1 isotype control antibodies were all purchased from Biointron as were the following recombinant proteins: mouse Fc-tagged huCD47 ECD, mouse Fc-tagged huSIRPα V1 ECD, and 6 × His tagged huSIRPα V8 ECD.